Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 54Biliary Tract Neoplasms 23Nasopharyngeal Carcinoma 22Cholangiocarcinoma 22Carcinoma, Non-Small-Cell Lung 22Urinary Bladder Neoplasms 18Breast Neoplasms 18Neoplasm Metastasis 17Lung Neoplasms 14Lymphoma, Large B-Cell, Diffuse 13Colorectal Neoplasms 12Carcinoma, Transitional Cell 12Non-Muscle Invasive Bladder Neoplasms 10Recurrence 8Ovarian Neoplasms 8Triple Negative Breast Neoplasms 7Sarcoma 7Gallbladder Neoplasms 7Neoplasms 6Hodgkin Disease 6Nasopharyngeal Neoplasms 5Bile Duct Neoplasms 5Adenocarcinoma 5Uterine Cervical Neoplasms 4Locally Advanced Pancreatic Cancer 4Endometrial Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Adenocarcinoma 3Osteosarcoma 3Lymphoma 3

Interventions

pembrolizumab 12Cisplatin 7Cetuximab 7Carboplatin 7Docetaxel 6Blood Specimen Collection 4Radiotherapy, Intensity-Modulated 3Paclitaxel 3toripalimab 2atezolizumab 2Radiotherapy 2Nivolumab 2Magnetic Resonance Spectroscopy 2Fluorouracil 2Drug Therapy 2tocilizumab 1regorafenib 1osimertinib 1lenvatinib 1fludarabine 1ficlatuzumab 1cemiplimab 1calcipotriene 1bintrafusp alfa protein, human 1avelumab 1alpha-2'-deoxythioguanosine 1aldesleukin 1aflibercept 1Watchful Waiting 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Squamous Cell × Gemcitabine × Clear all
NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Maia Biotechnology

Phase 3 Recruiting
300 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡